Serum Concentrations of IGF-1R, ERK2, and EGFR and Their Clinical Significance in Patients with Neuroendocrine Tumors-Reference-Cited by-同舟云学术

Serum Concentrations of IGF-1R, ERK2, and EGFR and Their Clinical Significance in Patients with Neuroendocrine Tumors

Published:2024-08-09 Issue:16 Volume:14 Page:6998
ISSN:2076-3417
Container-title:Applied Sciences
language:en
Short-container-title:Applied Sciences

Author:

Duszkiewicz Roksana¹,Strzelczyk Janusz²^ORCID,Chełmecka Elżbieta³^ORCID,Strzelczyk Joanna Katarzyna¹^ORCID

Affiliation:

1. Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana St., 41-808 Zabrze, Poland

2. Department of Endocrinology and Neuroendocrine Tumors, Department of Pathophysiology and Endocrinology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 35 Ceglana St., 40-514 Katowice, Poland

3. Department of Medical Statistics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 30 Ostrogórska St., 40-055 Katowice, Poland

Abstract

Neuroendocrine tumors are a heterogeneous group of tumors located mainly in the gastrointestinal tract or the respiratory system. We aimed to determine the concentrations of IGF-1R, ERK2, and EGFR using the ELISA method in serum samples from patients with NETs and from a control group. Results were evaluated with the selected demographic, clinicopathological, and biochemical characteristics. The analyses performed on a group of patients (80 in the study group and 62 in the control group) showed that the concentration of EGFR in patients with neuroendocrine tumors was significantly higher (p < 0.001) compared to the control group. Additionally, a significantly higher (p < 0.001) EGFR concentration was found in GEP-NET. Our results indicate that impaired EGFR signaling pathways are important in the context of neuroendocrine tumors. The data presented are a good starting point for further analysis of these proteins.

Funder

Medical University of Silesia

Publisher

MDPI AG

Link

https://www.mdpi.com/2076-3417/14/16/6998/pdf

Reference91 articles.

1. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin;Basu;Endocr. Relat. Cancer,2010

2. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours);Foltyn;Endokrynol. Pol.,2022

3. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement;Adaway;Ann. Clin. Biochem.,2016

4. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs);Tellez;Pancreas,2013

5. Sansone, A., Lauretta, R., Vottari, S., Chiefari, A., Barnabei, A., Romanelli, F., and Appetecchia, M. (2019). Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers, 11.